<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953312</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210522</org_study_id>
    <secondary_id>2021-A00674-37</secondary_id>
    <nct_id>NCT04953312</nct_id>
  </id_info>
  <brief_title>Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)</brief_title>
  <acronym>CALPRO</acronym>
  <official_title>Calprotectin Involvement in Emergency Hematopoiesis Observed in Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide new insights into the pathophysiology of emergency&#xD;
      hematopoiesis detected in severe COVID-19 patients. The investigators aim to explore the&#xD;
      ability of calprotectin to induce an immunosuppressive myeloid program at the hematopoietic&#xD;
      stem and progenitor cell (HSPC) level, and to identify the receptor(s) involved in this&#xD;
      effect. Since patients with a hematological malignancy demonstrate a very high propensity to&#xD;
      develop a severe COVID-19, the investigators will explore how HSPCs collected from patients&#xD;
      with a myeloid malignancy respond to calprotectin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emergency myelopoiesis in response to SARS-CoV-2 infection produce immunosuppressive myeloid&#xD;
      cells with accumulation of immature granulocytes and loss of non-classical monocytes.&#xD;
      Excessive release of calprotectin, the dimer of S100A8/A9 alarmins, by immature granulocytes&#xD;
      and activated monocytes reflects this situation. A role of calprotectin has been previously&#xD;
      described in the initiation and progression of chronic hematological malignancies such as&#xD;
      myelodysplastic syndromes.&#xD;
&#xD;
      To provide a rationale for the targeting of alarmin-driven signaling pathways and limit the&#xD;
      pathogenic inflammatory response to SARS-CoV-2 infection, the role of calprotectin in the&#xD;
      production of immunosuppressive cells from the bone marrow hematopoietic stem and progenitors&#xD;
      cells needs to be investigated in patients with severe COVID-19 in comparison with patients&#xD;
      with chronic myeloid malignancies (such as chronic myelomonocytic leukemia and&#xD;
      myelodysplastic syndromes) and with age-mached healthy controls.&#xD;
&#xD;
      A comprehensive and integrated multiomics approach will be used to decipher the features of&#xD;
      immunosuppressive cells and identify therapeutic targets in deregulated pathways.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differential gene expression and epigenetic signature of COVID-19 or leukemic versus normal HSC using CITE-seq and ATAC-seq</measure>
    <time_frame>12 months</time_frame>
    <description>Hematopoietic stem and progenitor cells from patients with severe or moderate COVID-19 or chronic myeloid malignancies or controls will be purified for analyses of transcriptome and chromatin conformation, and also functionally characterized using in vitro culture systems. Results will be compared between the three groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ex vivo testing of calprotectin-receptor interaction inhibitor</measure>
    <time_frame>During the last 6 months of the study</time_frame>
    <description>Expression of targeted receptors will be monitored by flow cytometry. Clinically developed compounds that could inhibit calprotectin effects will be tested in vitro.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Severe/Moderate Coronavirus According to the WHO Classification</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Old Age</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients (group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a recent diagnosis (&lt;7 days since first symptoms) of moderate or severe COVID-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic myeloid malignancies (group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults with chronic myeloid malignancies including myelodysplastic syndromes with low risk MDS ; high risk MDS according to IPSS-R or with dysplastic or proliferative chronic myelomonocytic leukemia according to WHO2016</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (group 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Age-matched healthy donors</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>blood</description>
    <arm_group_label>COVID-19 patients (group 1)</arm_group_label>
    <arm_group_label>Chronic myeloid malignancies (group 2)</arm_group_label>
    <arm_group_label>Control group (group 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria for all groups:&#xD;
&#xD;
          -  Adults ≥ 18 years&#xD;
&#xD;
          -  Dated and signed inform consent *&#xD;
&#xD;
               -  * : written informed consent of relative (trusted person, close family) in case&#xD;
                  of emergency procedure, by default emergency inclusion notified in medical file&#xD;
                  and pursuance consent sought.&#xD;
&#xD;
          -  Affiliation with a social security scheme&#xD;
&#xD;
        Criteria for control group:&#xD;
&#xD;
          -  Age-matched healthy donors&#xD;
&#xD;
        Criteria for chronic myeloid malignancies:&#xD;
&#xD;
          -  A diagnosis of low or high-risk myelodysplastic syndromes according to the WHO 2016&#xD;
             classification&#xD;
&#xD;
          -  A diagnosis of dysplastic or proliferative chronic myelomonocytic leukemia according&#xD;
             to WHO 2016&#xD;
&#xD;
        Criteria for COVID-19 patients:&#xD;
&#xD;
          -  Patients with a recent diagnosis (&lt;7 days since first symptoms) of moderate or severe&#xD;
             COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Minor patient or major under protection&#xD;
&#xD;
          -  Patients with COVID-19 infection and active cancer or a history of cancer within the&#xD;
             last 6 months&#xD;
&#xD;
          -  Patients with COVID-19 and severe comorbidities including cardiovascular or&#xD;
             respiratory diseases, unbalanced diabetes, obesity (IMC &gt;29)&#xD;
&#xD;
          -  Patient on AME (state medical aid)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela FONTENAY, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric SOLARY, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gustave Roussy Institut</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela FONTENAY, PhD</last_name>
    <phone>+33 1 58 41 20 04</phone>
    <email>michaela.fontenay@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle AUGER</last_name>
    <phone>+33 1 58 41 11 86</phone>
    <email>christelle.auger@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Institut</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie DROIN, PhD</last_name>
      <phone>+33 1 42 11 63 02</phone>
      <email>nathalie.droin@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Betty LEITE, Engineer</last_name>
      <phone>+33 1 42 11 63 02</phone>
      <email>GD-UGF@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Didier BOUSCARY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline CHARLIER-WOERTHER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tali-Anne SZWEBEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric PENE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cherifa CHEURFA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gfmgroup.org</url>
    <description>Groupe Francophone des Myélodysplasies: GFM is a cooperative group of the French Society of Hematology</description>
  </link>
  <reference>
    <citation>Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, Hénon C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V, Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, Pène F, Gachot B, André F, Zitvogel L, Ginhoux F, Fontenay M, Solary E. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell. 2020 Sep 17;182(6):1401-1418.e18. doi: 10.1016/j.cell.2020.08.002. Epub 2020 Aug 5.</citation>
    <PMID>32810439</PMID>
  </reference>
  <reference>
    <citation>Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, Blair C, Woodward W, Lezak SP, Lugogo NL, Woods RJ, Lood C, Knight JS, Kanthi Y. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. J Leukoc Biol. 2021 Jan;109(1):67-72. doi: 10.1002/JLB.3COVCRA0720-359R. Epub 2020 Sep 1.</citation>
    <PMID>32869342</PMID>
  </reference>
  <reference>
    <citation>Udeh R, Advani S, de Guadiana Romualdo LG, Dolja-Gore X. Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021 Feb 15;10(4). pii: 775. doi: 10.3390/jcm10040775. Review.</citation>
    <PMID>33672040</PMID>
  </reference>
  <reference>
    <citation>Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, Zarember KA, Alehashemi S, Oikonomou V, Desai JV, Canna SW, Shakoory B, Dobbs K, Imberti L, Sottini A, Quiros-Roldan E, Castelli F, Rossi C, Brugnoni D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Castagnoli R, Montagna D, Licari A, Marseglia GL, Gliniewicz EF, Shaw E, Kahle DE, Rastegar AT, Stack M, Myint-Hpu K, Levinson SL, DiNubile MJ, Chertow DW, Burbelo PD, Cohen JI, Calvo KR, Tsang JS; NIAID COVID-19 Consortium, Su HC, Gallin JI, Kuhns DB, Goldbach-Mansky R, Lionakis MS, Notarangelo LD. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021 Jan 11;6(1). pii: 144455. doi: 10.1172/jci.insight.144455.</citation>
    <PMID>33232303</PMID>
  </reference>
  <reference>
    <citation>Bauer W, Diehl-Wiesenecker E, Ulke J, et al. Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department. J Infect. 2020 Nov 17:S0163-4453(20)30711-8.</citation>
  </reference>
  <reference>
    <citation>Luis García de Guadiana Romualdo, Mulero MDR, Olivo MH, Rojas CR, Arenas VR, Morales MG, Abellán AB, Conesa-Zamora P, García-García J, Hernández AC, Morell-García D, Dolores Albaladejo-Otón M, Consuegra-Sánchez L. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. J Infect. 2021 Feb;82(2):e40-e42. doi: 10.1016/j.jinf.2020.08.010. Epub 2020 Aug 12.</citation>
    <PMID>32795482</PMID>
  </reference>
  <reference>
    <citation>Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Rev Clin Immunol. 2021 May;17(5):431-443. doi: 10.1080/1744666X.2021.1905526. Epub 2021 Apr 13. Review.</citation>
    <PMID>33750254</PMID>
  </reference>
  <reference>
    <citation>Kaya T, Yaylacı S, Nalbant A, Yıldırım İ, Kocayiğit H, Çokluk E, Şekeroğlu MR, Köroğlu M, Güçlü E. Serum calprotectin as a novel biomarker for severity of COVID-19 disease. Ir J Med Sci. 2021 Feb 27. doi: 10.1007/s11845-021-02565-8. [Epub ahead of print]</citation>
    <PMID>33641087</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calprotectin</keyword>
  <keyword>hematopoiesis</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

